154 related articles for article (PubMed ID: 15078184)
1. Transglutaminases - possible drug targets in human diseases.
Gentile V; Cooper AJ
Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):99-104. PubMed ID: 15078184
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Martin A; Romito G; Pepe I; De Vivo G; Merola MR; Limatola A; Gentile V
Curr Med Chem; 2006; 13(16):1895-902. PubMed ID: 16842200
[TBL] [Abstract][Full Text] [Related]
3. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
De Vivo G; Di Lorenzo R; Ricotta M; Gentile V
Curr Med Chem; 2009; 16(36):4767-73. PubMed ID: 19929789
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Iannaccone M; Serretiello E; De Vivo G; Martin A; Stefanile A; Titta F; Gentile V
Recent Pat CNS Drug Discov; 2013 Aug; 8(2):161-8. PubMed ID: 23688272
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Martin A; De Vivo G; Ricotta M; Iannuzzi M; Gentile V
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):195-202. PubMed ID: 20636272
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
De Vivo G; Gentile V
CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):370-5. PubMed ID: 18991665
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of cystamine in a murine model of Huntington's disease.
Dedeoglu A; Kubilus JK; Jeitner TM; Matson SA; Bogdanov M; Kowall NW; Matson WR; Cooper AJ; Ratan RR; Beal MF; Hersch SM; Ferrante RJ
J Neurosci; 2002 Oct; 22(20):8942-50. PubMed ID: 12388601
[TBL] [Abstract][Full Text] [Related]
8. Possible physiopathological roles of the transglutaminase activity in the etiopathogenesis of human neurodegenerative diseases.
Titta F; Iannaccone M; Martin A; Gentile V
Recent Pat CNS Drug Discov; 2014; 9(2):101-9. PubMed ID: 24924102
[TBL] [Abstract][Full Text] [Related]
9. Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Iannaccone M; Titta F; Serretiello E; Monfregola M; Gentile V
Recent Pat CNS Drug Discov; 2014; 9(2):76-84. PubMed ID: 25386917
[TBL] [Abstract][Full Text] [Related]
10. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
Karpuj MV; Becher MW; Springer JE; Chabas D; Youssef S; Pedotti R; Mitchell D; Steinman L
Nat Med; 2002 Feb; 8(2):143-9. PubMed ID: 11821898
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminases as targets for pharmacological inhibition.
Wodzinska JM
Mini Rev Med Chem; 2005 Mar; 5(3):279-92. PubMed ID: 15777262
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Iannaccone M; Titta F; Serretiello E; De Vivo G; Martin A; Gentile V
Recent Pat CNS Drug Discov; 2013 Dec; 8(3):235-42. PubMed ID: 24286449
[TBL] [Abstract][Full Text] [Related]
13. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Gibrat C; Cicchetti F
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):380-9. PubMed ID: 21111020
[TBL] [Abstract][Full Text] [Related]
14. The multifaceted role of transglutaminase in neurodegeneration: review article.
Karpuj M; Steinman L
Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
[TBL] [Abstract][Full Text] [Related]
15. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of gamma-glutamylamines in Huntington disease CSF.
Jeitner TM; Matson WR; Folk JE; Blass JP; Cooper AJ
J Neurochem; 2008 Jul; 106(1):37-44. PubMed ID: 18422943
[TBL] [Abstract][Full Text] [Related]
17. Transglutaminase inhibitors: a patent review.
Keillor JW; Apperley KY
Expert Opin Ther Pat; 2016; 26(1):49-63. PubMed ID: 26560530
[TBL] [Abstract][Full Text] [Related]
18. Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine.
Jeon JH; Lee HJ; Jang GY; Kim CW; Shim DM; Cho SY; Yeo EJ; Park SC; Kim IG
Exp Mol Med; 2004 Dec; 36(6):576-81. PubMed ID: 15675041
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase activity in aging articular chondrocytes and articular cartilage vesicles.
Rosenthal AK; Derfus BA; Henry LA
Arthritis Rheum; 1997 May; 40(5):966-70. PubMed ID: 9153560
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.
Hoffner G; André W; Vanhoutteghem A; Souès S; Djian P
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):217-31. PubMed ID: 19811443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
